Tillkännagivande • Aug 06
Waters Corporation Provides Earnings Guidance for the Third Quarter Ending October 3, 2026 and Full Fiscal Year Ending December 31, 2026 Waters Corporation provided earnings guidance for the third quarter ending October 3, 2026 and Full Fiscal Year ending December 31, 2026. For the quarter, Total Company reported revenue for the third quarter of 2026 is expected to be in the range of $1.745 billion to $1.762 billion.
For the Full-Year, total Company reported revenue for full-year 2026 is expected to be in the range of $6.415 billion to $6.476 billion. Reported Earnings • Aug 04
Second quarter 2026 earnings released: US$1.39 loss per share (vs US$2.47 profit in 2Q 2025) Second quarter 2026 results: US$1.39 loss per share (down from US$2.47 profit in 2Q 2025). Revenue: US$1.65b (up 113% from 2Q 2025). Net loss: US$136.0m (down 192% from profit in 2Q 2025). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Life Sciences industry in Europe. Tillkännagivande • Jul 28
Waters Corporation Launches Xevo TQ Absolute XR IVD Mass Spectrometer Waters Corporation announced the launch of the Xevo TQ Absolute XR IVD Mass Spectrometer, expanding its MassTrak IVD System portfolio of LC-MS/MS Systems with a solution that combines class-leading sensitivity and enhanced robustness for clinical applications. The new system builds on the industry-renowned step-change performance of the Xevo TQ Absolute IVD Mass Spectrometer, which established the benchmark for sensitivity among IVD-compliant tandem quadrupole mass spectrometers. Developed for routine laboratory testing requiring IVD-compliant systems, the Xevo TQ Absolute XR IVD System delivers exceptional trace-level analytical performance in complex biological matrices. With up to five times greater sensitivity than other instruments in its class, the system enables lower limits of detection and reliable quantification of challenging analytes from smaller sample volumes. This enhanced sensitivity is critical for applications requiring accurate measurement at very low concentrations, such as low-level estradiol testing for women's health and hormone-related cancer assessment, and hair toxicology for detecting drugs of abuse and documenting long-term exposure. Featuring the new StepWave XR Ion Guide, the Xevo TQ Absolute XR IVD System delivers improved robustness, enabling ion ratio consistency for up to six times longer compared with the Xevo TQ Absolute IVD System. This advancement gives laboratories greater confidence in consistent performance when analyzing complex clinical samples containing phospholipids, salts, and other matrix components. This new MassTrak LC-MS/MS IVD System includes the ACQUITY UPLC I-Class PLUS System with the Xevo TQ Absolute XR IVD Mass Spectrometer. The ACQUITY UPLC I-Class PLUS System is designed to deliver fast, accurate sample analysis that enhances mass spectrometer performance and simplifies the characterization of complex samples. Together, the integrated system delivers industry-leading sensitivity, enhanced robustness for complex sample matrices, and a user-friendly design that helps maximize laboratory uptime. Buy Or Sell Opportunity • Jul 16
Now 20% undervalued Over the last 90 days, the stock has risen 19% to €329. The fair value is estimated to be €413, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.8% over the last 3 years. Earnings per share has declined by 5.9%. For the next 3 years, revenue is forecast to grow by 17% per annum. Earnings are also forecast to grow by 25% per annum over the same time period. Tillkännagivande • Jul 02
Waters Corporation to Report Q2, 2026 Results on Aug 04, 2026 Waters Corporation announced that they will report Q2, 2026 results on Aug 04, 2026 Tillkännagivande • Jun 29
Waters Corporation(NYSE:WAT) dropped from Russell 3000 Growth Benchmark Waters Corporation(NYSE:WAT) dropped from Russell 3000 Growth Benchmark Buy Or Sell Opportunity • Jun 29
Now 20% undervalued Over the last 90 days, the stock has risen 25% to €323. The fair value is estimated to be €406, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.8% over the last 3 years. Earnings per share has declined by 5.9%. For the next 3 years, revenue is forecast to grow by 16% per annum. Earnings are also forecast to grow by 25% per annum over the same time period. Tillkännagivande • Jun 09
Waters Corporation Launches BioResolve Peptide and GTxResolve Lipid Phenyl-Hexyl+ and C18+ Columns Waters Corporation had announced the launch of the BioResolve Peptide and GTxResolve Lipid Phenyl-Hexyl+ and C18+ Columns, a first-of-its-kind reversed-phase (RP) column platform designed to tackle a persistent biopharmaceutical challenge: reliably separating structurally and chemically similar impurities in GLP-1 peptides, insulin, and lipid nanoparticles (LNPs) to support the development of safe, effective drug products. BioResolve Peptide and GTxResolve Lipid Columns help to overcome these limitations with ready-to-use methods that improve both resolution and speed while fitting into existing workflows. BioResolve Peptide and GTxResolve Lipid Columns are designed to resolve chemically similar GLP-1 impurities and LNP components faster when speed matters, and with extraordinary resolution when certainty is required. BioResolve Peptide and GTxResolve Lipid Columns use specially designed surface chemistries and superficially porous particles to deliver precise RP separations with selectivity for two difficult sample types. Available in Phenyl-Hexyl+ and C18+ chemistries with 230 Å pore size particles, they are designed to support efficient mass transfer, consistent performance across U(H)PLC and HPLC systems, and reliable, batch-tested results from early-stage research through manufacturing. GLP-1 peptides are especially challenging to analyze because many impurities differ by just one atom, while others have no difference in atomic composition and vary only in how their atoms are arranged spatially. BioResolve Peptide Phenyl-Hexyl+ and C18+ Columns are built to resolve these difficult impurities, with specialized 300 mm formats available when maximum separation performance and deeper impurity characterization are required. For LNP and lipid workflows, the charged surface of GTxResolve Columns helps sharpen peaks for ionizable lipids by reducing tailing. Their larger pore size makes it easier for a wide range of lipid molecules to move through the column, improving peak shape and resolving challenging co-elutions. In addition, the superficially porous particle design speeds the movement of molecules through the stationary phase, shortening run times without reducing selectivity. GTxResolve Lipid RP Columns have demonstrated strong performance for lipid quantitation and impurity analysis, with reduced run times and excellent peak shape. The ability to tune separations for specific lipid components, combined with compatibility across multiple detector platforms (UV, MS, ELSD, and CAD), provides significant flexibility for characterization of diverse lipid species. Waters' BioResolve Peptide and GTxResolve Lipid Columns will be available globally beginning June 9, 2026, starting with the 1.6 µm Phenyl-Hexyl+ phase. Tillkännagivande • Jun 04
Waters Corporation Announces FDA 510(k) Clearance Of BD BACTEC FXI Culture System Waters Corporation announced that the BD BACTEC FXI Culture System has received U.S. Food and Drug Administration (FDA) 510(k) clearance. This clearance enables commercialization in the U.S. and provides a new option for laboratories seeking a fully automated blood culture system designed to improve the speed, consistency, and accuracy of sepsis and bloodstream infection diagnostics in modern microbiology laboratories. Clinical study data showed that the BD BACTEC FXI Culture System reduced mean time to detection by approximately three hours (~15%) compared with the previous-generation BD BACTEC FX Blood Culture System (17 hours vs. 20 hours). Faster detection enables earlier pathogen identification and more timely targeted antimicrobial therapy for patients with suspected bloodstream infections and sepsis. Because each hour of delayed sepsis treatment increases mortality by 3.6% to 9.9%, faster diagnostic workflows are critical in acute care settings. The BD BACTEC FXI Culture System features a first-of-its-kind capability in a blood culture platform – an automated gravimetric measurement of individual blood culture vial volume. By objectively confirming blood volume in each vial, the system reduces pre-analytical variability and supports more consistent diagnostics and adherence to recommended collection practices. Designed for high-throughput microbiology labs, the BD BACTEC FXI Culture System fully automates vial loading, unloading, incubation, and detection alerts, with an automated loading capacity of up to 60 vials at a time, 50% more vials than the leading competitor. Available in 480- and 960-vial configurations, the BD BACTEC FXI Culture System delivers scalable efficiency while reducing manual intervention and increasing staff walk-away time. The BD BACTEC FXI Culture System was recently CE marked under the European Union's In Vitro Diagnostic Regulation (IVDR) and licensed by the Japan Pharmaceuticals and Medical Devices Agency (PMDA) for availability in Europe and Japan. The BD BACTEC FXI Culture System and BD BACTEC Blood Culture Vials are manufactured by Becton, Dickinson and Company or one of its affiliates or subsidiaries. BD is a trademark of Becton, Dickinson and Company. Waters is a trademark of Waters Corporation or its affiliates. All other marks are the property of their respective owners. The BD Biosciences and BD Diagnostic Solutions businesses have been acquired by Waters Corporation. Becton, Dickinson and Company or one of its affiliates or subsidiaries remains the legal manufacturer of Biosciences and Diagnostic Solutions products until all required regulatory transfers are completed. During this interim period, BD maintains full responsibility for all regulatory obligations of the legal manufacturer. Product information provided here is supplied under BD's regulatory authority. Reported Earnings • May 08
First quarter 2026 earnings released: US$0.88 loss per share (vs US$2.04 profit in 1Q 2025) First quarter 2026 results: US$0.88 loss per share (down from US$2.04 profit in 1Q 2025). Revenue: US$1.27b (up 92% from 1Q 2025). Net loss: US$72.0m (down 159% from profit in 1Q 2025). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe. Tillkännagivande • May 06
Waters Corporation Provides Earnings Guidance for the Second Quarter Ending July 4, 2026 and Full Year Ending December 31, 2026 Waters Corporation provided earnings guidance for the second quarter ending July 4, 2026 and full year ending December 31, 2026. For the quarter, the company expects total revenue for the second quarter of 2026 is expected to be in the range of $1.616 billion to $1.631 billion.
For the year, the company expects total revenue to be to be in the range of $6.405 billion to $6.455 billion on a reported basis. Tillkännagivande • Apr 15
Waters Corporation Debuts Industry-First Extended-Range MALS Detector for UHPLC/UPLC Powering Rapid Characterization of Large Molecules Waters Corporation announced the launch of the Waters omniDAWN Multi-Angle Light Scattering (MALS) Photometer, part of the Wyatt Technology Portfolio. Featuring 18 angles of detection, the omniDAWN Photometer is the first extended-range MALS detector for Ultra High Performance Liquid Chromatography (UHPLC) and Ultra Performance Liquid Chromatography (UPLC) workflows, delivering absolute molar mass and size measurements without compromising resolution or throughput. The omniDAWN MALS Photometer extends UPLC-compatible sizing ten-fold, from approximately 50 to 500 nm in radius, enabling reliable characterization of larger, more complex analytes such as protein aggregates, viral vectors, lipid nanoparticles (LNPs), and advanced materials. Because it provides absolute molar mass and size, the omniDAWN Photometer reduces reliance on column calibration standards and supports faster results and more confident comparisons, streamlining work across biosimilarity studies, antibody-drug conjugate (ADC) characterization, and viral vector analytics. Integrating seamlessly with Waters UPLC Systems and columns, the omniDAWN Photometer eliminates traditional trade-offs between dispersion, robustness, and analytical performance, delivering a complete solution for multi-attribute characterization with improved usability compared to micro-volume MALS approaches. When paired with UHPLC or UPLC Systems, the omniDAWN Photometer supports run times up to four times faster than conventional HPLC workflows, while reducing sample consumption by 30–50% and solvent use by approximately 40%. Its low dispersion design preserves resolution and sensitivity, while delivering high-quality data across complex samples. Sharper separations enhance the detection of low-level species, helping scientists distinguish monomer, aggregates, and fragments with greater clarity, supporting informed decision-making across discovery, development, and quality workflows. The omniDAWN Photometer is powered by ASTRA Software, built on more than 40 years of light scattering innovation. By integrating MALS with ultraviolet (UV) and refractive index (RI) detection, ASTRA Software enables comprehensive analysis of size, composition, and heterogeneity in a single run, with dedicated workflows for ADCs, LNPs, and viral vectors. The platform is 21 CFR Part 11 and EU Annex 11 compliant and will be compatible with Waters Empower Software later this year. The Waters omniDAWN MALS Photometer will be available globally in summer 2026. Tillkännagivande • Apr 10
Waters Corporation, Annual General Meeting, May 21, 2026 Waters Corporation, Annual General Meeting, May 21, 2026. Tillkännagivande • Apr 08
Waters Corporation Announces U.S. Food and Drug Administration Clearance of the Most Comprehensive At-Home Cervical Cancer Screening Tool, the Onclarity HPV Self-Collection Kit and FDA-Approved HPV Assay Waters Corporation announced that the U.S. Food and Drug Administration (FDA) has cleared the Onclarity HPV Self-Collection Kit and approved the BD Onclarity HPV Assay with extended genotyping for at-home use, marking a significant milestone in expanding access to cervical cancer screening, and removing barriers that currently prevent many individuals from receiving routine screening. Cervical cancer is largely preventable with regular screening and early detection of human papillomavirus (HPV), the virus responsible for nearly all cervical cancers. Approximately 60% of cervical cancer cases occur in individuals who are unscreened or under-screened. Expanding screening options and access, including at-home self-collection, has been identified by public health experts as an instrumental strategy for improving early detection and reducing cervical cancer deaths. The kit is tested with the BD Onclarity HPV Assay, which detects all of the high-risk, carcinogenic genotypes of HPV and is the only FDA-approved HPV assay to identify six individually and three groups of pooled results, making it the most comprehensive HPV screening tool available in the U.S. today. Samples are processed on the fully automated BD COR System, which uses advanced robotics to prepare, analyze, and report results while preserving specimen integrity and ensuring reliable, high-quality outcomes. Waters collaborated with the National Institutes of Health's (NIH) National Cancer Institute (NCI) through the Cervical Cancer 'Last Mile' Initiative SHIP Trial to evaluate the accuracy of self-collection for HPV testing. Waters is currently establishing partnerships to enable broader nationwide access to the Onclarity HPV Self-Collection Kit, which is expected to be available by prescription in the coming months. Covered by private insurance, Medicaid, and Medicare, the kit can be mailed directly to a patient's home, allowing them to collect a sample at their convenience and mail it to a laboratory for processing. Results are shared with the patient's healthcare provider to guide follow-up and care decisions. The Onclarity HPV Self-Collection Kit, Onclarity HPV Assay, and BD COR System are manufactured by Becton, Dickinson and Company or one of its affiliates or subsidiaries. Tillkännagivande • Mar 10
Waters Corporation Launches ARES-G3 Rheometer Waters Corporation launched the ARES-G3 Rheometer, part of the TA Instruments product line. This next-generation rheometer delivers industry-leading speed paired with best-in-class data to accelerate materials research and product development. Capturing up to 25,000 data points per second (10x more than its predecessor) and cutting standard test times by up to 80% through fully integrated Fast Frequency Chirps, the ARES-G3 Rheometer addresses pressing industry limitations. The ARES-G3 Rheometer enables shortened experiment times, increased lab throughput, and previously unobtainable measurements of fast-changing samples in a single test. Because it fully integrates a Fast Frequency Chirps solution into its enhanced TRIOS Software, the ARES-G3 Rheometer eliminates the need for multiple software licenses and training in advanced programming packages to capture and process data through rapid frequency sweeps. Routine quality control tests and data generation can also be completed up to 80% faster than before with some tests reduced from six hours to one; this translates to accelerated workflows that save teams hundreds of workdays per year under typical conditions, without sacrificing data quality. The ARES-G3 Rheometer can also perform many tests without requiring user calibrations, reducing margin for human error and increasing confidence in measurements. The ARES-G3 Rheometer builds on the flagship legacy of its predecessor, improving at-instrument control with a new touchscreen, enhancing data capture with hardware and software updates, and preserving its core proprietary, fully integrated dynamic mechanical analysis (DMA) capabilities and purpose-built hardware for both stress measurement and strain control. Retaining the best-in-class oven of the ARES-G2 Rheometer, this next-generation rheometer delivers low-oxygen atmosphere control and temperature uniformity, further simplifying the process of simulating real-world processing conditions, and enabling scientists to explore new rheological methods and gain a deeper understanding of structure-property relationships. All existing ARES-G2 Rheometer methods and fixtures remain fully compatible with the ARES-G3 Rheometer. The Waters TA Instruments ARES-G3 Rheometer is available for order. New Risk • Feb 15
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 65% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.6% average weekly change). Shareholders have been substantially diluted in the past year (65% increase in shares outstanding). Reported Earnings • Feb 13
Full year 2025 earnings released: EPS: US$10.80 (vs US$10.75 in FY 2024) Full year 2025 results: EPS: US$10.80 (up from US$10.75 in FY 2024). Revenue: US$3.17b (up 7.0% from FY 2024). Net income: US$642.6m (flat on FY 2024). Profit margin: 20% (down from 22% in FY 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 9.4% growth forecast for the Life Sciences industry in Europe. Tillkännagivande • Feb 09
Waters Corporation Appoints Claire M. Fraser to Its Board of Directors Waters Corporation announced the appointment of Claire M. Fraser, Ph.D., to its Board of Directors, effective upon the closing of the transaction. Dr. Fraser is a globally acclaimed genome scientist, with three decades of experience managing large research institutes. Most recently, she served as Director of The Institute for Genome Sciences, which she founded in 2007, at the University of Maryland School of Medicine, where she also served as a Professor of Medicine and Microbiology and Immunology. Dr. Fraser received a B.S. in Biology from Rensselaer Polytechnic Institute in Troy, NY, and a Ph.D. in Pharmacology from the State University of New York at Buffalo. Tillkännagivande • Jan 27
Waters Corporation to Report Q4, 2025 Results on Feb 09, 2026 Waters Corporation announced that they will report Q4, 2025 results on Feb 09, 2026 Tillkännagivande • Nov 12
Waters Corporation Boosts Lab Productivity and Sample Throughput with Launch of Its Charged Aerosol Detector Designed for Empower Software Waters Corporation announced the launch of its Charged Aerosol Detector (CAD) specifically designed for use with Waters Empower Software. Waters is the global market leader in chromatography software solutions for regulatory filings, as Empower Software is used to submit data for approximately 80% of novel drugs to regulatory authorities. The Waters CAD delivers sensitive, consistent, and reproducible measurement of analytes with little or no UV absorption, including sugars, lipids, impurities, and excipients, often without the need for sample pre-treatment. This makes CAD ideal for characterizing an exceptionally broad range of materials, from small molecule and biopharmaceutical formulations to food additives, nutrients, and environmental pollutants. The Waters CAD delivers competitive dynamic range and sensitivity, alongside optimized compatibility with MaxPeak™? High-Performance Surfaces that mitigate non-specific adsorption. The new detector can be used with a wide range of Waters liquid chromatography systems, including the Alliancetm iS HPLC System, the Arctm HPLC System, and all ACQUITY™? UPLC™? Systems. The seamless integration of this CAD with broadly-adopted Empower Software delivers an enhanced user experience, supported by Waters' leading support and service provision. Issues commonly seen in multi-vendor LC-CAD systems, including challenging set-up and dropped communication between detector and chromatograph - leading to interrupted sample sets and in some cases detector flooding - are significantly reduced when using a Waters LC-CAD configured with Empower CDS. In addition, methods developed for existing CADs can be easily transferred using built-in tools. The introduction of the Waters Charged Aerosol Detect reinforces the Company's commitment to provide the world's widest range of liquid chromatography detectors, all compatible with Empower Software - enabling scientists to fully characterize the physical and chemical properties of molecules within a secure and compliant workflow. Availability: The Waters Charged Aerosoldetector (CAD) is available for pre-order now, with shipments available by April 2026. Tillkännagivande • Nov 05
Waters Corporation Raises Earnings Guidance for the Fourth Quarter and Full Year Ending December 31, 2025 Waters Corporation raised earnings guidance for the fourth quarter and full year ending December 31, 2025. For the quarter, The company expects constant currency sales growth in the range of +5.0% to +7.0%. Net of currency translation, fourth quarter 2025 reported sales growth is expected in the range of +5.2% to +7.2%. The company expects GAAP earnings per diluted share in the range of $4.10 - $4.20.
The Company is raising its full-year 2025 constant currency sales growth guidance to the range of +6.7% to +7.3%. Net of currency translation, the Company is raising its full-year 2025 reported sales growth to the range of +6.5% to +7.1%. The company expects GAAP earnings per diluted share in the range of $11.10 - $11.20. Tillkännagivande • Oct 01
Waters Corporation to Report Q3, 2025 Results on Nov 04, 2025 Waters Corporation announced that they will report Q3, 2025 results on Nov 04, 2025 Tillkännagivande • Jul 15
Waters Corporation (NYSE:WAT) entered into a definitive agreement to acquire Biosciences and Diagnostics Solutions Business of Becton Dickinson and Company in a transaction valued at $17.5 billion. Waters Corporation (NYSE:WAT) entered into a definitive agreement to acquire Biosciences and Diagnostics Solutions Business of Becton Dickinson and Company in a transaction valued at $17.5 billion on July 13, 2025. BD’s shareholders are expected to own approximately 39.2% of the combined company, and existing Waters shareholders are expected to own approximately 60.8% of the combined company. BD will also receive a cash distribution of approximately $4 billion prior to completion of the combination, subject to adjustment for cash, working capital, and indebtedness. Waters is expected to assume approximately $4 billion of incremental debt, which would result in a net-debt-to-adjusted EBITDA leverage ratio for the combined company of 2.3x at closing.
The transaction is subject to receipt of required regulatory approvals, Waters shareholder approval, Any applicable waiting period under the HSR Act and satisfaction of other customary closing conditions. It was subject to approval by Boards of Directors of Waters and BD and has been unanimously approved by the Boards of Directors of both Waters and BD. The transaction is expected to close around the end of the first quarter of calendar year 2026.
Upon closing of the transaction, Udit Batra will lead the new entity, and Amol Chaubal will serve as SVP and Chief Financial Officer. Executives from both companies will serve in key leadership roles to be announced at a later date. Up to two BD designees will join the Waters Board of Directors upon closing. The combined company will continue to operate under the Waters name and retain its listing on the New York Stock Exchange under the ticker symbol WAT. Waters’ headquarters will remain in Milford, Massachusetts.
Barclays is serving as financial advisor and Daniel E. Wolf, P.C., David M. Klein, P.C., Allie M. Wein, P.C. and Steven M. Choi of Kirkland & Ellis LLP is serving as legal advisor to Waters. Citi and Evercore is acting as lead financial advisor to BD. David K. Lam and Jenna E. Levine of Wachtell, Lipton, Rosen & Katz is serving as legal advisor to BD. Tillkännagivande • May 23
Waters Corporation (NYSE:WAT) acquired Halo Labs. Waters Corporation (NYSE:WAT) acquired Halo Labs on May 21, 2025. Halo Labs, Aura, and Wyatt Technology are trademarks of Waters Technologies Corporation.
Waters Corporation (NYSE:WAT) completed the acquisition of Halo Labs on May 21, 2025. Tillkännagivande • May 21
Waters Corporation (NYSE:WAT) acquired Optofluidics, Inc. Waters Corporation (NYSE:WAT) acquired Optofluidics, Inc. on May 21, 2025.
Waters Corporation (NYSE:WAT) completed the acquisition of Optofluidics, Inc. on May 21, 2025. 
